Bioactive compounds from Streptomyces nasri and its mutants with special reference to proteopolysaccharides

Polish Journal of Microbiology

Volumn 55, Issue 3, 2006, Pages 179-187

  Gohar, Yousry ^a   Beshay, Usama ^b   Daba, Ayman ^b   Hafez, Elsayed ^b  

^a Alexandria University Faculty Of Science   (Egypt)

^b Universities and Research centers District   (Egypt)

Author keywords

Antimicrobial activity; Bioactive compound; Microbial polysaccharides; Streptomyces sp. mutations

Indexed keywords

ACRIDINE ORANGE; EXOPOLYSACCHARIDE; POLYSACCHARIDE; PROTEOPOLYSACCHARIDE DERIVATIVE; SULFORHODAMINE B;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM MUTANT; BRAIN TUMOR; CHEMICAL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; KUWAIT; MOLECULAR WEIGHT; MORPHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POLYACRYLAMIDE GEL ELECTROPHORESIS; STREPTOMYCES; STREPTOMYCES NASRI; TUMOR CELL LINE; ULTRAVIOLET RADIATION;

ANTI-INFECTIVE AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE; HUMANS; POLYSACCHARIDES; SOIL MICROBIOLOGY; STREPTOMYCES; STRUCTURE-ACTIVITY RELATIONSHIP;

STREPTOMYCES; STREPTOMYCES SP.;

EID: 33845628524     PISSN: 17331331     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Adachi Y., N. Ohno, M. Ohsawa, S. Oikawa and T. Yadomae. 1990. Change of biological activities of (1-3)-β-D-glucan from Grifola frondosa upon molecular weight reduction by heat treatment. Chem. Pharm. Bull. 38: 477-481.
2. Amade P., M. Mallea and N. Bouaicha. 1994. Isolation, structural identification and biological activity of two metabolites produced by Penicillium olsonii Bainier and Sartory. J. Antibiot. 47: 201-207.
3. Babineau T.J., A. Hackford, A. Kenler, B. Bistrian, R.A. Forse, P.G. Fairchild, S. Heard, M. Kerorack, P. Causha and P. Benotti. 1994a. A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients. Arch. Surg. 129: 1204-1210.
4. Babineau T.J., P. Marcello, W. Swails, A. Kenler, B. Bistrian and R.A. Forse. 1994b. Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients. Ann. Surg. 220: 601-609.
5. Browder W., D. Williams, H. Pretus, G. Olivero, F. Enrichens, P. Mao and A. Franchello. 1990. Beneficial effect of enhanced macrophage function in the trauma patient. Ann. Surg. 211: 605-613.
6. Chihara G., Y.Y. Maeda, J. Hamuro, T. Shiio, T. Suga, N. Takasuka and T. Sasaki. 1987. Antitumour and metastasis-inhibitory activities of lentinan as immunomodulator: An overview. Cancer Detect. Prev. 1: 423-442.
7. Chihara G., Y.Y. Maeda, T. Suga and J. Hamuro. 1989. Lentinan as a host defense potetiator (HDP). Int. J. Immunother. 4: 145-150.
8. DelaCruz N., G.F. Payne, J.M. Smith and S.J. Coppella. 1992. Bioprocess development to improve foreign protein production from recombinant Streptomyces. Biotechnol. Prog. 8: 307-315.
9. Franz G. 1989. Polysaccharides in pharmacy: Current applications and future concepts. Planta Med. 55: 493-497.
10. Grabley S. and R. Thiericke. 1999. Drug Discovery from Nature, Chapter 7: Secondary metabolites-from past to present, Springer-Verlag Berlin Heidelberg, New York. 117-123.
11. Hamano K., H. Gohra, T. Katoh, Y. Fujimura, N. Zempo and K. Esato. 1999. The preoperative administration of lentinan ameliorated the impairment of natural killer activity after cardiopulmonary bypass. Int. J. Immunopharmacol. 21: 531-540.
12. Hashem M.A. and A. Diab. 1973. Some physiological studies on Streptomyces nasri sp. nov. from the desert of Kuwait. Zentralbl. Bakteriol. Parasit. Abstrakt. 128: 356-362.
13. Held T. and H.J. Kutzner. 1991. Genetic recombination in Streptomyces michiganensis DSM 40015 revealed three genes responsible for the formation of melanin. J. Basic Microbiol. 31: 127-134.
14. Itoh W., I. Sugawara, S. Kimura, K. Tabata, A. Hirata, T. Kojima, S. Mori and K. Shimada. 1990. Immunopharmacological study of sulfated schizophyllan (SPG) I. Its action as a mitogen and anti-HIV agent. Int. J. Immunopharmacol. 12: 225-233.
15. Kimura Y., H. Tojima, S. Fukase and K. Takeda. 1994. Clinical evaluation of sizofilan as assistant immunotherapy in treatment of head and neck cancer. Acta Otolaryngol. Suppl. 511: 175-178.
16. Laemmli U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
17. Mizuno T., P. Yeohlui, T. Kinoshita, C. Zhuang and Y. Moyuzumi. 1996. Antitumour activity and chemical modification of polysaccharides from niohshimeji mushroom, Tricholoma giganteum. Biosci. Biotechnol. Biochem. 60: 30-33.
18. Nakano T., K. Oka, K. Hanba and S. Morita. 1996. Intratumoral administration of sizofilan activates Langerhan cell and T-cell infiltration in cervical cancer. Clin. Immunol. Immunopathol. 79: 79-86.
19. Ohno N., M. Furukawa, N. Miura, Y. Asachi, M. Motoi and T. Yadomae. 2001. Antitumour β-glucan from the cultured fruit body of Agaricus blazei. Biol. Pharm. Bull. 24: 820-828.
20. Ooi V.E. and F. Liu. 2000. Immunomodulation and anti-cancer activity of polysaccharide-protein complexes. Curr. Med. Chem. 7: 715-729.
21. Ross G.D., V. Vetvicka, J. Yan, Y. Xia and J. Vetvicková. 1999. Therapeutic intervention with complement and β-glucan in cancer. Immunopharmacology 42: 61-74.
22. Sacramento D.R., R.R. Rodrigues, M.D. Wigg, L.F. Linhares, M.G. Santos, L.T. Semado and A.J. Silva. 2004. Antimicrobial and antiviral activities of an actinomycete (Streptomyces sp.) isolated from Brazilian tropical forest soil. World J. Microbiol. Biotechnol. 20: 225-229.
23. Sanglier J.J., E.M. Wellington, V. Behal, H.P. Fiedler, R. Ellouz Ghorbel, C. Finance, M. Hacene, A. Kamoum, C. Kelly, D.K. Mercer, S. Prinzis and C. Trigo. 1993. Novel bioactive compounds from actinomycetes. Res. Microbiol. 144: 661-663.
24. Skehan P., R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney and M.R. Boyd. 1990. New colorimetric cytotoxicity assay for anti-cancer drug screening. J. Natl. Cancer Inst. 82: 1107-1112.
25. Sutherland I.W. 1990. Biotechnology of Microbial Exopolysaccharides. Cambridge University Press. Cambridge
26. Sutherland I.W. 1998. Novel and applied application of polysaccharide. Trends Biotechnol. 16: 41-46.
27. Sutherland I.W. 2001. Microbial polysaccharides from Gram-negative bacteria. Int. Dairy J. 11: 663-674.
28. van Geel-Schutten G.H., F. Flesch, B. Brink, M.R. Smith and L. Dijkhuizen. 1998. Screening and characterization of Lactobacillus strains producing large amounts of exopolysaccharides. Appl. Microbiol. Biotechnol. 50: 697-703.
29. Venkateswarlu G., P.S. Murali Krishna, G. Sharma and L.V. Rao. 2000. Improvement of rifamycin B production using mutant strains of Amycolatopsis mediterranei. Bioprocess Eng. 23: 315-318.
30. Vetvicka V. 2001. β-glucans as immunomodulators. The Journal of the American Nutraceutical Association (JANA) 3: 24-31
31. Zhang Y., H. Li and W. Lu. 1993. Taxonomic study on strain 1254 and its mutant 113. Acta Microbiol. Sin. 33: 13-21.